SEOM clinical guidelines in early stage breast cancer (2018)

Francisco Ayala de la Peña ^[1] ; R. Andrés ^[2] ; J. A. Garcia-Sáenz ^[3] ; L. Manso ^[7] ; M. Margelí ^[4] ; E. Dalmau ^[8] ; S. Pernas ^[4] ; A. Prat ^[5] ; S. Servitja ^[6] ; E. Ciruelos ^[7]
1. [1] Hospital Morales Meseguer
  
  Hospital Morales Meseguer
  
  Murcia, España
2. [2] Hospital Clínico Universitario Lozano Blesa
  
  Hospital Clínico Universitario Lozano Blesa
  
  Zaragoza, España
3. [3] Hospital Clínico San Carlos de Madrid
  
  Hospital Clínico San Carlos de Madrid
  
  Madrid, España
4. [4] Institute Catalá Oncología
  
  Institute Catalá Oncología
  
  Barcelona, España
5. [5] Hospital Clinic Barcelona
  
  Hospital Clinic Barcelona
  
  Barcelona, España
6. [6] Hospital del Mar
  
  Hospital del Mar
  
  Barcelona, España
7. [7] Hospital Universitario Madrid
8. [8] Hospital Universitari Barcelona
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 1 (January 2019), 2019, págs. 18-30
Idioma: inglés
Texto completo no disponible (Saber más ...)

Resumen
- Breast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially curable stages. Nevertheless, around 20–30% of patients will relapse despite appropriate locoregional and systemic therapies. A better knowledge of this disease is improving our ability to select the most appropriate therapy for each patient with a recent diagnosis of an early stage breast cancer, minimizing unnecessary toxicities and improving long-term efficacy.